XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Cash flows from operating activities:              
Net loss $ (32,237,098) $ (30,469,871) $ (35,534,533) $ (40,649,317) $ (62,706,969) $ (76,183,850)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation         916,019 1,410,649  
Amortization of intangible assets         0 145,417  
Amortization of operating lease right-of-use assets         672,336 739,469  
Impairment of intangible assets         0 1,984,444  
Non-cash stock-based compensation         4,039,486 6,727,000  
Non-cash interest on senior convertible notes         (355,654) 93,489  
Amortization of discounts on investments         (1,154,822) (2,402,451)  
Loss on sales of short-term investments         692,557 3,853,543  
Loss on disposal of fixed assets         21,930 334,297  
Loss (gain) on equity investment in affiliated entity 334,294   (156,745)   460,312 (773,384)  
Net unrealized gain on available-for-sale equity securities 20,820   (922,941)   (480,057) (4,141,156)  
Changes in operating assets and liabilities:              
Accounts receivable, including from affiliated entities         631,563 6,621,990  
Prepaid expenses and other current assets, including from affiliated entities         48,237 41,191,898  
Other assets         19,400 17,154  
Accounts payable and accrued expenses, including due to affiliated entities         (2,362,045) (43,955,799)  
Accrued clinical trial expenses         3,134,266 (4,421,691)  
Operating lease right-of-use assets and liabilities, net         (458,376) (1,406,066)  
Grant funding liability, including from affiliated entity         (87,489) 1,185,913  
Net cash used in operating activities         (56,969,306) (68,979,134)  
Cash flows from investing activities:              
Purchases of investments         (29,359,747) (106,741,680)  
Proceeds from sale or maturity of investments         85,196,528 173,898,007  
Purchases of capital assets         (487,832) (320,898)  
Proceeds from sale of capital assets         0 6,071,000  
Net cash provided by investing activities         55,348,949 72,906,429  
Cash flows from financing activities:              
Repayment of convertible senior notes         (16,415,000) 0  
Proceeds from issuance of pre-funded warrants, net of issuance costs         16,146,397 0  
Proceeds from issuance of common stock, net of issuance costs   5,200,000     22,284,801 2,915,179 $ 5,500,000
Proceeds from stock option exercises         67,675 0  
Taxes paid related to net share settlement of equity awards         (414,377) (456,996)  
Net cash provided by financing activities         21,669,496 2,458,183  
Effect of exchange rate changes on cash and cash equivalents         32,403 (2,294)  
Increase in cash and cash equivalents         20,081,542 6,383,184  
Cash and cash equivalents, beginning of period   $ 14,310,862   $ 46,329,359 14,310,862 46,329,359 46,329,359
Cash and cash equivalents, end of period $ 34,392,404   $ 52,712,543   34,392,404 52,712,543 $ 14,310,862
Supplemental disclosures:              
Interest paid         533,487 533,487  
Issuance of common stock as part of litigation settlement         $ 0 $ 14,000,000